In related news, Director Noah G. Levy bought 69,087 shares of the stock in a transaction dated Tuesday, November 24th. The stock was purchased at an average cost of $3.65 per share, with a total value of $252,167.55. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 21.60% of the stock is currently owned by insiders.Several institutional investors and hedge funds have recently modified their holdings of MACK. Private Advisor Group LLC purchased a new stake in Merrimack Pharmaceuticals in the second quarter worth about $25,000. LVW Advisors LLC purchased a new stake in Merrimack Pharmaceuticals in the third quarter worth about $80,000. Bronte Capital Management Pty Ltd. purchased a new stake in Merrimack Pharmaceuticals in the third quarter worth about $2,052,000. Nantahala Capital Management LLC lifted its stake in Merrimack Pharmaceuticals by 0.6% in the third quarter. Nantahala Capital Management LLC now owns 751,943 shares of the biopharmaceutical company’s stock worth $3,008,000 after acquiring an additional 4,308 shares during the period. Finally, Western Standard LLC lifted its stake in Merrimack Pharmaceuticals by 3.1% in the second quarter. Western Standard LLC now owns 869,354 shares of the biopharmaceutical company’s stock worth $2,895,000 after acquiring an additional 26,441 shares during the period. 45.83% of the stock is owned by hedge funds and other institutional investors.
Shares of MACK traded up $2.41 during trading hours on Wednesday, reaching $6.49. 77,082,195 shares of the company traded hands, compared to its average volume of 370,655. Merrimack Pharmaceuticals has a 12-month low of $1.49 and a 12-month high of $7.10. The stock’s fifty day moving average price is $3.83 and its 200 day moving average price is $3.66.
https://www.americanbankingnews.com/2020/12/02/merrimack-pharmaceuticals-sees-unusually-high-options-volume-nasdaqmack.html
Recent MACK News
- Form 15-12G - Securities registration termination [Section 12(g)] • Edgar (US Regulatory) • 05/20/2024 08:05:28 PM
- Form 25 - Notification of the removal from listing and registration of matured, redeemed or retired securities • Edgar (US Regulatory) • 05/10/2024 08:45:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/10/2024 08:43:01 PM
- Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock • Business Wire • 05/10/2024 08:30:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/09/2024 11:45:25 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 11:43:00 AM
- Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Subject to Receipt of Stockholder Approval of Plan of Dissolution • Business Wire • 05/09/2024 11:30:00 AM
- Merrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of Dissolution • Business Wire • 04/30/2024 09:15:00 PM
- Merrimack Receives $225 Million Milestone Payment from Ipsen • Business Wire • 03/27/2024 08:30:00 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 03/07/2024 09:42:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 09:39:03 PM
- Merrimack Reports Full Year 2023 Financial Results • Business Wire • 03/07/2024 09:30:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/07/2024 09:15:29 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 03/07/2024 05:29:51 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/05/2024 09:44:02 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:20:24 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 02/13/2024 09:26:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 09:22:56 PM
- Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) • Business Wire • 02/13/2024 09:18:00 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 01/25/2024 09:05:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/28/2023 09:05:12 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 12/13/2023 09:05:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/11/2023 09:05:08 PM
FEATURED Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM